Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2025 was $172 million, down from $193.7 million in the prior year, primarily due to softening customer demand [13] - Adjusted EBITDA was $5.2 million, compared to $8.2 million in the prior year, with adjusted EBITDA margins at 3%, down 120 basis points from 4.2% [13] - Free cash flow for the quarter was $17.3 million, a significant increase from $0.8 million in the prior year [15] - Net loss for the quarter was $4.1 million, or a loss of $0.12 per diluted share, compared to a net loss of $1.3 million, or a loss of $0.04 per diluted share in the prior year [14] Business Line Data and Key Metrics Changes - Global Seating segment revenues decreased by 10% to $74.5 million, with adjusted operating income increasing by $200,000 to $3.1 million [15][16] - Global Electrical segment revenues remained flat at $53.6 million, with adjusted operating income increasing by $400,000 to $1.2 million [16] - Trim Systems and Components revenues decreased by 24% to $43.9 million, with adjusted operating income down by $3.7 million to $300,000 [18] Market Data and Key Metrics Changes - The Class 8 heavy truck build forecast for 2025 indicates a 24% decline in year-over-year volumes, with flat projections for 2026 and a 12% improvement expected in 2027 [20] - The construction market is expected to decline by approximately 5% to 15%, while the agriculture market is anticipated to decline in the same range due to economic factors [20] Company Strategy and Development Direction - The company is focused on improving cash generation and aligning SG&A structure with current revenue, expecting $30 million in working capital reduction [22] - Strategic portfolio actions taken in 2024 are expected to lower cost structures and improve earnings power as market demand recovers [22] - The company is actively pursuing new business opportunities and maintaining strong relationships with customers to gain market share [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged broader market and macroeconomic uncertainties but remains optimistic about long-term recovery in construction and agriculture markets [20] - The company is adjusting its full-year 2025 revenue guidance to a range of $650 million to $670 million, down from $660 million to $690 million [24] - Free cash flow guidance for 2025 has been increased to at least $30 million, reflecting strong year-to-date performance [25] Other Important Information - The company completed a debt refinancing during the second quarter, providing more financial flexibility for operational initiatives [8] - The net leverage ratio at the end of Q2 was 4.8x, down from 5.0x at the end of Q1 [15] Q&A Session Summary Question: Are you seeing new business being bid and won? - Management confirmed ongoing new business wins and a robust pipeline, although some implementation dates have shifted due to economic conditions [30][32] Question: How much of the expected cost savings are permanent? - Management indicated that cost savings are both material and permanent, with ongoing actions to optimize SG&A and manufacturing overhead [35][36] Question: How is the tariff renegotiation process progressing? - Management expects to complete tariff renegotiations by the end of the year, with ongoing assessments of impacts and mitigation strategies [38][39] Question: How did July perform relative to Q2? - Management noted increased downtime in July due to OEMs' schedules, requiring adjustments in manufacturing and inventory management [42] Question: Is there a natural replacement cycle for Class 8 trucks? - Management acknowledged a replacement cycle exists, but current economic uncertainty is causing delays in purchases [53][55]

Financial Data and Key Metrics Changes - The company's reported and adjusted net income for Q2 2025 was $8 million, resulting in earnings per diluted share of $0.23, compared to adjusted net income of $39 million or $1.15 per share in 2024 [14] - Revenues increased slightly due to the addition of Skyland, despite overall lower commodity prices [14] - Adjusted EBITDA for Q2 was $65 million, down from $98 million in 2024 [15] Business Line Data and Key Metrics Changes - The Agribusiness segment reported adjusted pretax income of $17 million, down from $33 million in 2024, with adjusted EBITDA of $46 million compared to $56 million in 2024 [18][20] - The Renewables segment generated pretax income of $10 million, down from $23 million in 2024, with EBITDA of $30 million compared to $52 million last year [21][22] Market Data and Key Metrics Changes - The company noted improved fertilizer results due to increased volume and margin driven by high corn plantings [9] - The wheat harvest was completed, and facilities are prepared for increased corn volumes expected at harvest [9] Company Strategy and Development Direction - The company has acquired its partner's share of four ethanol plants, which is expected to be immediately accretive to EPS and align reported EPS and EBITDA [12][13] - The company is focused on pursuing additional opportunities in ethanol and renewable feedstocks, with plans to improve efficiencies and lower carbon intensity [24][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for the second half of the year, anticipating improvements in the Agribusiness segment as the fall harvest approaches [23] - The company is evaluating additional growth projects and acquisitions aligned with its strategy, with a target of achieving a run rate EPS of approximately $4.3 per share by 2026 [27][28] Other Important Information - The company generated cash flow from operations of $43 million in Q2, down from $89 million in 2024, but continues to demonstrate positive cash flows throughout the ag cycle [16] - Capital spending for Q2 was $49 million, up from $29 million in 2024, with expectations to reach $200 million for the year [17] Q&A Session Summary Question: Did the timing of the ethanol transaction correlate with regulatory tailwinds? - Management indicated that while they have been looking at ethanol capacity for eight quarters, the recent regulatory changes did not materially affect the transaction timing [32] Question: Can you characterize the non-strategic exits in the Agribusiness segment? - Management noted a financial impact of about $7 million from minority investments and a few million dollars from the sale of underperforming facilities [34][35] Question: What is the outlook for merchandising and storage in the second half of the year? - Management expects improved opportunities for both merchandising and storage due to a large corn crop [38] Question: Why was acquiring the balance of the ethanol assets the right move now? - Management stated that acquiring the remaining 50% of the ethanol plants allows for better capital deployment and full earnings benefits without integration risk [42] Question: What is the updated outlook for ethanol margins? - Management believes the second half of 2025 will be better than the first half, with opportunities to drive more free cash flow from the plants [49] Question: How does the Port of Houston investment work with lower soybean meal prices? - Management explained that the price of soybean meal will drive it to export parity, making the investment competitive despite lower prices [53] Question: What was the revenue contribution from Skyland in the quarter? - Management reported revenue of about $200 million from Skyland in each of the first two quarters, with a revised EBITDA outlook for the full year of $25 million to $30 million [62]

Aramark (ARMK) Q3 2025 Earnings Call August 05, 2025 08:30 AM ET Speaker0Good morning, and welcome to Aramark's Third Quarter Fiscal twenty twenty five Earnings Results Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, I'd like to inform you that this conference is being recorded for rebroadcast and that all participants are in a listen only mode. We will open the conference call for questions at the conclusion of the company's remarks. I will now turn the call ove ...

Financial Data and Key Metrics Changes - Curis reported a net loss of $8.6 million or $0.68 per share for Q2 2025, compared to a net loss of $11.8 million or $2.03 per share for the same period in 2024, indicating an improvement in financial performance [11] - Research and development expenses decreased to $7.5 million in Q2 2025 from $10.3 million in Q2 2024, primarily due to lower employee-related costs and clinical expenses [11] - General and administrative expenses also decreased to $3.5 million in Q2 2025 from $4.8 million in Q2 2024, reflecting reduced employee-related and legal costs [12] Business Line Data and Key Metrics Changes - The company is focused on the "take aim lymphoma" study evaluating emigosertib in combination with ibrutinib for patients with primary CNS lymphoma (PCNSL), with plans to enroll 30 to 40 additional patients over the next 12 to 18 months [5][6] - In the AML segment, emivocertib showed a 38% composite complete response (CR) rate in relapsed/refractory AML patients with FLT3 mutations, compared to 21% for gilteritinib, indicating a competitive edge [8][9] Market Data and Key Metrics Changes - The company is exploring emivacertib's potential in high-risk myelodysplastic syndromes (MDS) following the failure of the Varonis study, which has generated interest in combining azacitidine with emivacertib [10] - The competitive landscape in CLL is evolving with the introduction of BTK degraders and next-generation BCL2 inhibitors, but the company believes there is still room for its combination therapy [18][20] Company Strategy and Development Direction - Curis aims to improve the standard of care for CLL and NHL patients by adding emivacertib to BTK inhibitors, potentially allowing patients to achieve deeper responses and reduce the risk of resistance [7] - The company is also planning a registrational study comparing emivacertib to gilteritinib in the relapsed/refractory AML setting, indicating a strategic focus on expanding its treatment options [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing discussions with the FDA and EMA regarding accelerated submissions for the lymphoma study, despite the current uncertain regulatory environment [39] - The company believes its lead indication in NHL, particularly in PCNSL where there are no approved drugs, positions it favorably for future growth [39] Other Important Information - Curis completed a registered direct offering and private placement in July 2025, raising approximately $6 million, which, along with existing cash, is expected to fund operations into 2026 [12] - The company has over 30 clinical sites open for patient enrollment in the lymphoma study, with expectations of enrolling one patient per site per year due to the ultra-rare nature of the indication [24] Q&A Session Summary Question: What do you think the bar would be for the BTK combination study in CLL? - Management believes that adding emivacertib to a commercially available BTK inhibitor can lead to minimal residual disease (MRD) negativity or complete remissions, addressing an unmet medical need in CLL [16][17] Question: Can you provide any color on enrollment progression for the lymphoma study? - Enrollment is steady but challenging due to the ultra-rare population, with expectations of one patient per site per year [24][30] Question: How do you plan to prioritize development between PCNSL and CLL? - The company is actively discussing how to allocate resources efficiently, given the compelling data and multiple potential studies [48] Question: What is the status of discussions with the FDA regarding accelerated approval? - Management confirmed that discussions with the FDA remain positive and aligned with key activities [39] Question: Are there any updates on the investigator-sponsored solid tumor studies? - There are no current updates, but the company is hopeful for data from at least one study this year [51]

Financial Data and Key Metrics Changes - For the second quarter, the company reported GAAP net income attributable to common shareholders of $20 million, or $2.4 per share fully diluted, reflecting an annualized ROE of 17% [6][23] - Adjusted pretax income was $16 million, with an annualized adjusted ROE of 14%, impacted by $4 million from market volatility on originations revenue and margins [7][26] - Book value increased to $60 per share, up 5% year over year [7] Business Line Data and Key Metrics Changes - The servicing segment contributed $31 million to adjusted pretax income for the quarter, with forward servicing experiencing growth in average UPB [30] - Originations team delivered 35% year-over-year growth, compared to the industry's 23% growth [14] - Consumer Direct's funded volume was up 2.4 times versus the previous year, indicating strong recapture performance [15][17] Market Data and Key Metrics Changes - The Mortgage Bankers Association Refinance Application Index was up 43% over the prior year, indicating strong origination volumes despite market volatility [9] - Industry originations volume growth estimates have been lowered to 14% year over year due to interest rate expectations and slower home sales [10] Company Strategy and Development Direction - The company is focused on maintaining agility to find opportunities for shareholder value creation amid market volatility [10][36] - Continued investment in technology and process optimization is aimed at enhancing customer experience and improving scalability [14][20] - The company is increasing its owned MSR portfolio to grow book earnings and book value, while also pursuing new subservicing clients [12][31] Management's Comments on Operating Environment and Future Outlook - Management expects continued interest rate volatility and uncertainty, but believes the balanced business model is well-positioned for the dynamic market environment [10][36] - The company is optimistic about its potential for growth and shareholder returns, reaffirming its annual adjusted ROE guidance [35][34] Other Important Information - The company has been recognized for its industry-leading servicing performance by Fannie Mae, Freddie Mac, and HUD [19] - The MSR hedge strategy has been effective in minimizing the impact of interest rates on MSR valuation [33] Q&A Session Summary Question: Inquiry about professional services expenses - Management noted that professional expenses can vary based on financing structures and legal fees, with no significant issues in the current quarter [38] Question: Clarification on deferred tax assets - Management explained that counterparties generally view the increase in deferred tax assets as an improvement in total equity, and detailed the components that affect the valuation allowance [39][40] Question: M&A activity in servicing - Management indicated that M&A activity in servicing is influenced by supply and demand dynamics in the marketplace, with potential consolidation expected due to prolonged high interest rates [44][46]

Financial Data and Key Metrics Changes - Surgery Partners reported Q2 2025 net revenue of $826 million, an increase of 8.4% compared to Q2 2024, and adjusted EBITDA of $129 million, reflecting a 9% growth year-over-year [6][25]. - The adjusted EBITDA margin improved to 15.6%, up 10 basis points from the previous year [25]. - The company ended the quarter with $250 million in cash and total liquidity of $645 million [25][26]. Business Line Data and Key Metrics Changes - Same facility revenue growth was 5.1%, driven by a 3.4% increase in surgical case volume and a 1.6% increase in rates [24][25]. - Total joint procedures grew by 26% year-over-year, indicating strong demand in orthopedic surgeries [9]. - The company performed nearly 173,000 surgical cases in Q2 2025, a 3.8% increase from the previous year [24]. Market Data and Key Metrics Changes - The total addressable market for Surgery Partners is estimated to exceed $150 billion, with a current market size of over $40 billion [21]. - The company has limited exposure to Medicaid, accounting for less than 5% of revenue, which mitigates risks from regulatory changes [17]. - Proposed changes by CMS could add 276 procedures to the ASC covered list, enhancing the company's market position [18]. Company Strategy and Development Direction - The company focuses on three growth pillars: organic growth, margin improvement, and M&A activities [5][14]. - Surgery Partners plans to deploy $200 million in acquisitions for 2025, with a disciplined approach to ensure long-term value [15][29]. - The company is actively evaluating its asset portfolio to optimize operations and reduce leverage [21][44]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the current regulatory environment, with minimal exposure to tariff-related price increases [16][17]. - The company anticipates continued growth in same facility revenue, aiming for the high end of the 6% growth target for the full year [8][25]. - Management highlighted the importance of physician recruitment and the positive impact of new facilities on long-term growth [11][20]. Other Important Information - Surgery Partners opened eight de novo facilities in 2024 and has 10 more under construction, focusing on higher acuity specialties [12][20]. - The company recorded a 27% sequential decrease in transaction and integration costs, indicating improved efficiency in M&A activities [15][16]. - The strategic review process concluded with a reaffirmation of the company's value creation opportunities as a publicly traded entity [20][22]. Q&A Session Summary Question: What is the pace of acquisitions and how should it be modeled going forward? - Management indicated that while the pace of acquisitions has been slower, they remain confident in achieving the $200 million target for the year, emphasizing the importance of finding the best deals [32][34]. Question: What are the economics of de novo facilities and their impact on margins? - Management explained that de novo facilities take time to ramp up but are expected to contribute positively to margins as they focus on higher acuity procedures [35][39]. Question: Are there any service lines considered less core during portfolio optimization? - Management stated they are evaluating opportunities to maximize long-term shareholder value, which may include partnerships or sales in certain markets [42][44]. Question: What is the company's exposure to health exchange volume and its potential impact? - Management noted that their exposure to health exchange volume is limited and not a significant part of their business, indicating minimal risk from potential declines in exchange membership [97]. Question: What drove the increase in operating expenses and variability in other OpEx? - Management clarified that fluctuations in operating expenses are due to various miscellaneous items and that the increase in professional fees is related to newly acquired surgical facilities [84][86].

Financial Data and Key Metrics Changes - Marriott reported a second quarter global RevPAR increase of 1.5%, driven by nearly 2% ADR growth, despite a 30 basis point decline in occupancy [16][5] - Total gross fee revenue increased by 4% year over year to $1.4 billion, reflecting rooms growth and higher RevPAR [16][17] - Adjusted EBITDA rose by 7% to $1.42 billion [17][23] Business Line Data and Key Metrics Changes - RevPAR in the luxury segment increased by 4%, while select service and extended stay RevPAR in the US and Canada declined by approximately 1.5% year over year [7][8] - International RevPAR rose over 5%, with APAC seeing a 9% increase and EMEA a 7% increase [6][5] - Owned, leased, and other revenue, net of expenses, rose by 14% compared to the prior year, driven by improved performance at various hotels [17][16] Market Data and Key Metrics Changes - RevPAR in Greater China declined by 0.5% year over year due to a weaker macro environment, while the US and Canada region's RevPAR was flat year over year [7][6] - Government room nights in the US and Canada were down 16% year over year in the second quarter [19][66] - Group revenues for 2026 are pacing up 8% in the US and Canada, indicating a positive outlook for future periods [19][45] Company Strategy and Development Direction - The company is focused on enhancing its technology transformation, including a multi-year project on loyalty, reservations, and PMS systems [30][31] - Marriott is expanding its luxury portfolio and has plans to open an additional 27 luxury properties this year [12][11] - The introduction of the Marriott Media Network aims to connect brands with audiences throughout the guest journey, leveraging insights into traveler behavior [13][55] Management's Comments on Operating Environment and Future Outlook - Management expects full year RevPAR growth to be in the lower end of the prior range, between 1.5% to 2.5% over last year, with stronger growth anticipated internationally [9][17] - The company anticipates a flat to 1% increase in global RevPAR for the third quarter, with a more optimistic outlook for the fourth quarter due to holiday shifts and major events [18][19] - Management expressed confidence in the resilience of the group segment, despite macroeconomic uncertainties [86][85] Other Important Information - The company announced the retirement of CFO Leeny Oberg, with a transition plan in place [14][15] - The pipeline reached a record of over 590,000 rooms, with 40% under construction [9][10] - The company is committed to maintaining its investment-grade rating while returning excess capital to shareholders [25][24] Q&A Session Summary Question: Technology transformation project status and expected changes - Management is in the midst of a multi-year transformation of key systems, with a focus on enhancing guest and owner experiences through new technology [30][31] Question: Implications of recent legislation on development and renovations - The passage of the legislation has reduced uncertainty, potentially driving more renovation capital and development optimism among owners [39][40] Question: Group business trends and future bookings - Group revenues for 2026 are tracking positively, with no significant cancellations noted, indicating a stable outlook [45][46] Question: Marriott Media Network potential - Early interest from prospective advertisers has exceeded expectations, indicating a promising future for the network [51][54] Question: Commitment to residential branding despite volatility - Management remains excited about the residential business, emphasizing its long-term value despite short-term fluctuations [58][60] Question: Business transient trends and outlook - Business transient RevPAR was down 1% excluding government demand, but overall corporate travel is returning to normal levels [64][67]

Financial Data and Key Metrics Changes - In Q2 2025, the company reported revenue of $800.4 million, a decline of 0.7% compared to $806 million in the prior year quarter. Adjusted EBITDA was $155.5 million, with an adjusted EBITDA margin of 19.4%, down from 20.5% in Q2 2024 [21][23][24] - Free cash flow for Q2 was $73.3 million, exceeding expectations, and the company is on track to meet its free cash flow guidance for FY 2025 [6][24] Business Line Data and Key Metrics Changes - The Sleep Health segment saw net revenue increase by 0.9% to $334.7 million, with 128,000 new setups, the highest in two years [22][23] - The Respiratory Health segment's net revenue increased by 5.6% to $170.5 million, with a record oxygen census of 329,000 patients [22][23] - The Diabetes Health segment experienced a decline of 4.1% in net revenue to $145 million, although there are signs of recovery in new starts and resupply retention [22][23] - The Wellness at Home segment's net revenue decreased by 7.2% to $150.3 million, impacted by the sale of certain non-core assets [22][23] Market Data and Key Metrics Changes - The company is gaining momentum in non-acquired revenue growth, particularly through a new capitated agreement expected to generate over $1 billion in revenue over five years [7][27] - The new partnership is projected to elevate capitated revenue to at least 10% of total revenue, increasing the mix of recurring revenue [7][27] Company Strategy and Development Direction - The company is focused on three strategic levers: accelerating non-acquired revenue growth, enhancing profitability, and strengthening the balance sheet [6] - A standard operating model is being rolled out to improve labor productivity and operational consistency across regions [11] - The company is actively engaged in policy advocacy and preparing for potential impacts from upcoming CMS competitive bidding rules [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the competitive landscape and emphasized the importance of scale in responding to economic pressures [16] - The company anticipates a ramp-up in revenue from the new capitated agreement starting in 2026, with expectations of at least $200 million in annual revenue [27][30] Other Important Information - The company reduced its debt by $150 million in Q2 2025, with a total reduction of $345 million over the last six quarters [13][25] - The tax law changes are expected to significantly reduce cash taxes and improve free cash flow over the next few years [17] Q&A Session Summary Question: Details on the $200 million revenue from the new capitated deal - Management confirmed that revenue will ramp up starting in Q1 2026, with full service expected by 2027, and the agreement is structured on a per member per month basis [33][36][40] Question: Impact of EBITDA guidance change - The $20 million reduction in adjusted EBITDA guidance is primarily due to the timing of payer rate negotiations and the need for infrastructure investments to support the new contract [46][48] Question: Market growth and share performance - The company reported a 3% increase in new starts, with expectations for continued strength in the second half of the year as operational changes take effect [50][52] Question: Competitive bidding and pricing dynamics - Management indicated that they are well-positioned to handle potential pricing pressures due to their scale and ongoing operational improvements [55][58] Question: M&A environment and opportunities - The company is seeing increased inbound opportunities and remains disciplined in evaluating potential acquisitions that align with its core competencies [65][66]

Financial Data and Key Metrics Changes - Total operating expenses increased to $5.5 million in Q2 2025 from $4 million in Q2 2024 [26] - Research and development (R&D) costs decreased to $1 million in Q2 2025 from $2.1 million in Q2 2024, primarily due to reduced costs associated with the ReAssure trial [26] - General and administrative (G&A) costs rose to $4.2 million in Q2 2025 from $1.9 million in Q2 2024, driven by pre-commercialization activities [26] - Net loss on a US GAAP basis was $6.5 million in Q2 2025 compared to a net loss of $5 million in Q2 2024 [27] - Non-GAAP net loss was $5.1 million in Q2 2025, up from $3.8 million in Q2 2024, mainly due to higher G&A expenses [27] - Cash and cash equivalents stood at $13 million as of June 2025, expected to fund operations into 2026 [28] Business Line Data and Key Metrics Changes - The company is preparing to launch Orlynda, targeting the uncomplicated urinary tract infection market in the U.S. [6][9] - The market generates approximately 40 million prescriptions annually, with about 26 million for at-risk patients [10] - The initial launch phase will focus on 20 targeted geographic territories, primarily in major metropolitan areas across seven states [12] Market Data and Key Metrics Changes - The uncomplicated urinary tract infection market has not seen a new branded oral treatment in over 25 years, indicating a significant opportunity for Orlynda [11] - Rising rates of antimicrobial resistance are eroding the efficacy of existing treatments, highlighting the need for new therapies [11] Company Strategy and Development Direction - The company aims to successfully launch Orlynda to address unmet needs in the uncomplicated urinary tract infection market [8] - A commercial supply agreement has been executed with ACS Dabfahr for the manufacturing of Orlynda, ensuring a reliable supply chain [18] - The company has received FDA market exclusivity for Orlynda, which will last until October 2034 [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of Orlynda and its potential to meet significant market needs [24] - The company is focused on optimizing physician targeting and resource allocation in key geographies to maximize revenue generation [16] - Management highlighted the importance of speed to therapy for patients suffering from uncomplicated urinary tract infections [17] Other Important Information - The company has deferred a $20 million regulatory payment to Pfizer, now due in October 2029, alleviating near-term financial obligations [21] - The company is seeking authorization for an additional 80 million shares to ensure financial flexibility for strategic objectives [29] Q&A Session Summary - No questions were registered during the Q&A session, indicating a lack of immediate inquiries from investors [32]

Financial Data and Key Metrics Changes - The company reported consolidated net sales of $1,100,000,000 for the second quarter, representing a 5% increase year over year [27] - Adjusted EBITDA for the quarter was $121,000,000, or 11% of net sales [33] - GAAP net income was $58,000,000, or $2.29 earnings per diluted share, compared to $61,000,000, or $2.40 per diluted share in the prior year [32] - Gross margins decreased to 24.4% from 25.3% year over year, primarily due to executive separation costs and changes in product mix [30] Business Line Data and Key Metrics Changes - RV OEM net sales totaled $840,000,000, up 5% from the same period in 2024, driven by market share gains [27] - Aftermarket net sales were $268,000,000, an increase of 4% year over year, primarily due to product innovations and expanding relationships [30][12] - Adjacent Industries OEM net sales increased by 10% year over year to $336,000,000, largely due to recent acquisitions [30] Market Data and Key Metrics Changes - North American RV sales were up 5%, while overall RV sales increased by 3% year over year [9] - The marine market experienced a 15% decline in sales due to inflation and high interest rates affecting retail demand [30] - The company expects softness in the marine market to continue for the balance of the year [16] Company Strategy and Development Direction - The company aims to achieve $5,000,000,000 in organic revenue by 2027, focusing on strategic acquisitions and product innovations [4][38] - A tariff mitigation strategy has been implemented to diversify the supply chain and minimize pricing impacts on customers [6] - The company is committed to reducing exposure to China from 24% in 2024 to 10% by 2025 through supply chain diversification [6] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for the second half of the year, noting that inflation and tariff uncertainties continue to pressure consumer behavior [23] - The company anticipates a gradual recovery in demand, with July 2025 sales up 5% year over year [24] - Management believes the toughest part of the cycle is behind them, positioning the company for success as volumes normalize [24] Other Important Information - The company generated $155,000,000 in operating cash flow, supported by improved working capital discipline [19] - A $300,000,000 share repurchase program was announced, with $128,000,000 executed year to date [34] - The company is focused on maintaining a strong financial foundation while driving growth and returning capital to shareholders [19] Q&A Session Summary Question: Inventory levels and potential restock impact - Management noted that dealers remain cautious with inventory levels, and any restock will likely be slow and gradual once demand improves [42][45] Question: Margin perspective and tariff impact - The company indicated that tariff impacts have increased to 290 basis points, primarily due to changes in government tariffs [58][59] Question: Sales growth and RV model year changeover - Management confirmed that the recent RV model year changeover did not significantly impact sales in Q2 or Q3 [60] Question: Trends in single axle and multi-axle RVs - Management reported a slight improvement in the mix of multi-axle units, with single axle units decreasing to about 20.5% in Q2 [66][67] Question: Aftermarket activity from previous years' buyers - Management indicated that there is less aftermarket opportunity for single axle trailers, but the overall aftermarket continues to grow [74] Question: Contribution of acquisitions to sales growth - Management estimated that 3% to 4% of the recent sales growth was attributable to acquisitions [79] Question: Future revenue targets and wholesale shipment volumes - The company expects to return to a normalized wholesale shipment range of 400,000 to 415,000 units over the next two to three years [83]